Exposure to varenicline protects against locomotor alteration in a MPTP mouse model of Parkinson's disease

The beneficial effects of drugs that act via nicotinic acetylcholine receptors (nAChRs) on Parkinson's disease (PD) symptomatology may explain the negative correlation between cigarette smoking and risk of this neurological condition. Varenicline, an α4β2 nAChR partial agonist approved for smoking cessation treatments, could be valuable for PD treatment. Here, we investigated varenicline effects in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) PD mouse model. From postnatal day (PN) 90 to PN119, male C57BL/6 mice were exposed daily to varenicline (2 mg/kg) by gavage. After that, MPTP was injected (30 mg/kg, ip) once a day for five days. At PN125, locomotor and anxiety-like effects were assessed with the open field test. At PN126, immobile behavior was assessed with the forced swimming test. At PN127, the frontal cerebral cortex was collected to evaluate dopamine and DOPAC levels. To verify whether varenicline was protective during the MPTP insult, a separate group of MPTP animals received varenicline from PN90 to PN124. MPTP reduced cortical dopamine content and increased dopamine turnover. Those effects were not reversed by varenicline treatment. Interestingly, varenicline reversed the MPTP-induced hyperactivity in the open field. Both maintenance of varenicline treatment during MPTP exposure or its interruption before MPTP exposure elicited similar results. No alterations were observed in anxiety-like behavior or in immobility time. Altogether, these findings suggested that varenicline treatment reduced the MPTP-induced hyperactivity, but did not protect against dopaminergic damage. Based on this partial protective effect, varenicline could exert neuroprotective effects on circuits that control motor activity in PD.

Saved in:
Bibliographic Details
Main Authors: Ribeiro-Carvalho,A., Leal-Rocha,P.H., Isnardo-Fernandes,J., Araújo,U.C., Abreu-Villaça,Y., Filgueiras,C.C., Manhães,A.C.
Format: Digital revista
Language:English
Published: Associação Brasileira de Divulgação Científica 2021
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2021001200614
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0100-879X2021001200614
record_format ojs
spelling oai:scielo:S0100-879X20210012006142021-12-01Exposure to varenicline protects against locomotor alteration in a MPTP mouse model of Parkinson's diseaseRibeiro-Carvalho,A.Leal-Rocha,P.H.Isnardo-Fernandes,J.Araújo,U.C.Abreu-Villaça,Y.Filgueiras,C.C.Manhães,A.C. Parkinson's Disease Dopamine Neuroprotection Varenicline Nicotine The beneficial effects of drugs that act via nicotinic acetylcholine receptors (nAChRs) on Parkinson's disease (PD) symptomatology may explain the negative correlation between cigarette smoking and risk of this neurological condition. Varenicline, an α4β2 nAChR partial agonist approved for smoking cessation treatments, could be valuable for PD treatment. Here, we investigated varenicline effects in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) PD mouse model. From postnatal day (PN) 90 to PN119, male C57BL/6 mice were exposed daily to varenicline (2 mg/kg) by gavage. After that, MPTP was injected (30 mg/kg, ip) once a day for five days. At PN125, locomotor and anxiety-like effects were assessed with the open field test. At PN126, immobile behavior was assessed with the forced swimming test. At PN127, the frontal cerebral cortex was collected to evaluate dopamine and DOPAC levels. To verify whether varenicline was protective during the MPTP insult, a separate group of MPTP animals received varenicline from PN90 to PN124. MPTP reduced cortical dopamine content and increased dopamine turnover. Those effects were not reversed by varenicline treatment. Interestingly, varenicline reversed the MPTP-induced hyperactivity in the open field. Both maintenance of varenicline treatment during MPTP exposure or its interruption before MPTP exposure elicited similar results. No alterations were observed in anxiety-like behavior or in immobility time. Altogether, these findings suggested that varenicline treatment reduced the MPTP-induced hyperactivity, but did not protect against dopaminergic damage. Based on this partial protective effect, varenicline could exert neuroprotective effects on circuits that control motor activity in PD.info:eu-repo/semantics/openAccessAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research v.54 n.12 20212021-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2021001200614en10.1590/1414-431x2021e11679
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Ribeiro-Carvalho,A.
Leal-Rocha,P.H.
Isnardo-Fernandes,J.
Araújo,U.C.
Abreu-Villaça,Y.
Filgueiras,C.C.
Manhães,A.C.
spellingShingle Ribeiro-Carvalho,A.
Leal-Rocha,P.H.
Isnardo-Fernandes,J.
Araújo,U.C.
Abreu-Villaça,Y.
Filgueiras,C.C.
Manhães,A.C.
Exposure to varenicline protects against locomotor alteration in a MPTP mouse model of Parkinson's disease
author_facet Ribeiro-Carvalho,A.
Leal-Rocha,P.H.
Isnardo-Fernandes,J.
Araújo,U.C.
Abreu-Villaça,Y.
Filgueiras,C.C.
Manhães,A.C.
author_sort Ribeiro-Carvalho,A.
title Exposure to varenicline protects against locomotor alteration in a MPTP mouse model of Parkinson's disease
title_short Exposure to varenicline protects against locomotor alteration in a MPTP mouse model of Parkinson's disease
title_full Exposure to varenicline protects against locomotor alteration in a MPTP mouse model of Parkinson's disease
title_fullStr Exposure to varenicline protects against locomotor alteration in a MPTP mouse model of Parkinson's disease
title_full_unstemmed Exposure to varenicline protects against locomotor alteration in a MPTP mouse model of Parkinson's disease
title_sort exposure to varenicline protects against locomotor alteration in a mptp mouse model of parkinson's disease
description The beneficial effects of drugs that act via nicotinic acetylcholine receptors (nAChRs) on Parkinson's disease (PD) symptomatology may explain the negative correlation between cigarette smoking and risk of this neurological condition. Varenicline, an α4β2 nAChR partial agonist approved for smoking cessation treatments, could be valuable for PD treatment. Here, we investigated varenicline effects in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) PD mouse model. From postnatal day (PN) 90 to PN119, male C57BL/6 mice were exposed daily to varenicline (2 mg/kg) by gavage. After that, MPTP was injected (30 mg/kg, ip) once a day for five days. At PN125, locomotor and anxiety-like effects were assessed with the open field test. At PN126, immobile behavior was assessed with the forced swimming test. At PN127, the frontal cerebral cortex was collected to evaluate dopamine and DOPAC levels. To verify whether varenicline was protective during the MPTP insult, a separate group of MPTP animals received varenicline from PN90 to PN124. MPTP reduced cortical dopamine content and increased dopamine turnover. Those effects were not reversed by varenicline treatment. Interestingly, varenicline reversed the MPTP-induced hyperactivity in the open field. Both maintenance of varenicline treatment during MPTP exposure or its interruption before MPTP exposure elicited similar results. No alterations were observed in anxiety-like behavior or in immobility time. Altogether, these findings suggested that varenicline treatment reduced the MPTP-induced hyperactivity, but did not protect against dopaminergic damage. Based on this partial protective effect, varenicline could exert neuroprotective effects on circuits that control motor activity in PD.
publisher Associação Brasileira de Divulgação Científica
publishDate 2021
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2021001200614
work_keys_str_mv AT ribeirocarvalhoa exposuretovareniclineprotectsagainstlocomotoralterationinamptpmousemodelofparkinsonsdisease
AT lealrochaph exposuretovareniclineprotectsagainstlocomotoralterationinamptpmousemodelofparkinsonsdisease
AT isnardofernandesj exposuretovareniclineprotectsagainstlocomotoralterationinamptpmousemodelofparkinsonsdisease
AT araujouc exposuretovareniclineprotectsagainstlocomotoralterationinamptpmousemodelofparkinsonsdisease
AT abreuvillacay exposuretovareniclineprotectsagainstlocomotoralterationinamptpmousemodelofparkinsonsdisease
AT filgueirascc exposuretovareniclineprotectsagainstlocomotoralterationinamptpmousemodelofparkinsonsdisease
AT manhaesac exposuretovareniclineprotectsagainstlocomotoralterationinamptpmousemodelofparkinsonsdisease
_version_ 1756391644600467456